Comprehensive PET imaging for diverse tauopathies

Hitoshi Shimada^1,2)

¹⁾Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University
²⁾Department of Functional Brain Imaging Research (DOFI), Institute for Quantum Medical Science, National Institutes for Quantum and Radiological Science and Technology (QST)

Tau pathologies are pathognomonic hallmarks of diverse tauopathies, including Alzheimer's disease (AD) and non-AD tauopathies such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD).　Tau pathologies have been implicated in causing disruption of brain environment such as neuroinflammation and synaptopathy leading to neuronal death, and tau alterations are considered crucial targets for imaging and therapy.　In this review, a series of clinical tau PET data is presented.　In addition, the impact of tau PET on drug discovery and clinical practice in this area and future directions are discussed.

Address correspondence to Dr. Hitoshi Shimada, Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University(1-757 Asahimachi-dohri, Chuo-ku, Niigata, Niigata 951-8585, Japan)